About
Team
Portfolio
News
Contact
Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region
March 8, 2021
|
In
Portfolio Company News
|
By
usvpAdminer
Prev
Next
Cookies are used on our website. Press Accept if you consent to the use of cookies, press Decline if you do not consent to the use of cookies.
Accept
Decline